eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
2/2017
vol. 9
 
Share:
Share:
more
 
 
abstract:
Case report

Electronic brachytherapy management of atypical fibroxanthoma: report of 8 lesions

Stephen Doggett, James Brazil, Marketa Limova, Leah Press, Sidney Smith, Jeremy Peck

J Contemp Brachytherapy 2017; 9, 2: 158–160
Online publish date: 2017/01/25
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose: To evaluate the suitability of treating atypical fibroxanthoma (AFX), an uncommon skin malignancy, with electronic brachytherapy.

Material and methods: From Feb 2013 to Sep 2014, we were referred a total of 8 cases of AFX in 7 patients, all involving the scalp. All of them were treated with electronic brachytherapy 50 Kev radiations (Xoft Axxent®, Fremont, California). All lesions received 40 Gy in two fractions per week with 5mm margins.

Results: At a median follow-up of 23.7 months, the local recurrence rate is 12.5%. The single lesion that failed was not debulked surgically prior to electronic brachytherapy.

Conclusions: To our knowledge, this is the first report in the literature on the use of radiation therapy as curative primary treatment for AFX. No contraindication to the use of radiations is found in the literature, with surgery being the sole treatment for AFX noted. Our recurrence rate is 0% for debulked lesions. Risk of recurrence is mitigated with surgical debulking prior to brachytherapy. Electronic brachytherapy appears to be a safe and effective treatment for debulked AFX. Multiple excisions, skin grafting, and wound care can be avoided in elderly patients by the use of electronic brachytherapy.
keywords:

atypical fibroxanthoma, electronic brachytherapy, radiation therapy, skin

references:
Withers AH, Brougham ND, Barber RM et al. Atypical fibroxanthoma and malignant fibrous histiocytoma. J Plast Reconstr Aesthet Surg 2011; 64: e273-278.
Ziemer M. Atypical fibroxanthoma. J Dtsch Dermatol Ges 2012; 10: 537-550 [Article in English, German].
Ang GC, Roenigk RK, Otley CC et al. More than 2 decades of treating atypical fibroxanthoma at mayo clinic: what have we learned from 91 patients? Dermatol Surg 2009; 35: 765-772.
Sakamoto A. Atypical fibroxanthoma. Clin Med Oncol 2008; 2: 117-127.
Koch M, Freundl AJ, Agaimy A et al. Atypical Fibroxanthoma – Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy. Anticancer Res 2015; 35: 5717-5735.
Hollmig ST, Sachdev R, Cockerell CJ et al. Spindle cell neoplasms encountered in dermatologic surgery: a review. Dermatol Surg 2012; 38: 825-850.
Withers AH, Brougham ND, Barber RM et al. Atypical fibroxanthoma and malignant fibrous histiocytoma. J Plast Reconstr Aesthet Surg 2011; 64: e273-278.
Davidson JS, Demsey D. Atypical fibroxanthoma: clinicopathologic determinants for recurrence and implications for surgical management. J Surg Oncol 2012; 105:559-562.
Wollina U, Schönlebe J, Koch A et al. Atypical fibroxanthoma: a series of 25 cases. J Eur Acad Dermatol Venereol 2010; 24: 943-946.
Mahalingam S, Shah A, Stewart A. Atypical fibroxanthoma: a case series and review of literature. Auris Nasus Larynx 2015; 42: 469-471.
Hilgers M, Wahl RU, Megahed M. Atypical fibroxanthoma of the scalp: overview and recent developments. Hautarzt 2014; 65: 1008-1010 [Article in German].
Doggett S, Willoughby M, Willoughby C et al. Incorporation of Electronic Brachytherapy for Skin Cancer into a Community Dermatology Practice. J Clin Aesthet Dermatol 2015; 8: 28-32.
Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C et al. Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. J Contemp Brachytherapy 2016; 8: 48-55.
Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C et al. Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. J Contemp Brachytherapy 2015; 7: 231-238.
Pons-Llanas O, Ballester-Sánchez R, Celada-Álvarez FJ et al. Clinical implementation of a new electronic brachytherapy system for skin brachytherapy. J Contemp Brachytherapy 2015; 6: 417-423.
Ahmad S, Johnson D, Hiatt JR et al. Comparison of tumor and normal tissue dose for accelerated partial breast irradiation using an electronic brachytherapy eBx source and an Iridium-192 source. J Appl Clin Med Phys 2010; 11: 3301.
Johnson M, Ahmad S, Johnson D. SU-E-T-388: Evaluation of electronic brachytherapy dose distributions in tissue equivalent materials. Med Phys 2015; 42: 3423.
Rong Y, Welsh JS. Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer treatment. Med Phys 2010; 37: 5509-5517.
Holt RW, Thomadsen BR, Orton CG. Point/counterpoint. Miniature x-ray tubes will ultimately displace Ir-192 as the radiation sources of choice for high dose rate brachytherapy. Med Phys 2008; 35: 815-817.
Bhatnagar A, Loper A. The initial experience of electronic brachytherapy for the treatment of non-melanoma skin cancer. Radiat Oncol 2010; 5: 87.
Strimling R, et al. Initial experience of Electronic Brachytherapy for the treatment of 508 non-melanoma skin cancers in 308 patients. Presented at the American Academy of Dermatology Annual Meeting [poster presentation 2013]. March 20-23, 2015, San Francisco, California.
 
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe